- Home
- TREE vs IGMS Comparison
TREE vs IGMS Comparison
Compare TREE & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TREE
- IGMS
- Stock Information
- Founded
- TREE 1996
- IGMS 1993
- Country
- TREE United States
- IGMS United States
- Employees
- TREE N/A
- IGMS N/A
- Industry
- TREE Finance: Consumer Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- TREE Finance
- IGMS Health Care
- Exchange
- TREE Nasdaq
- IGMS Nasdaq
- Market Cap
- TREE 573.8M
- IGMS 528.6M
- IPO Year
- TREE N/A
- IGMS 2019
- Fundamental
- Price
- TREE $40.46
- IGMS $7.48
- Analyst Decision
- TREE Buy
- IGMS Buy
- Analyst Count
- TREE 8
- IGMS 8
- Target Price
- TREE $64.00
- IGMS $16.25
- AVG Volume (30 Days)
- TREE 361.0K
- IGMS 213.0K
- Earning Date
- TREE 10-31-2024
- IGMS 11-08-2024
- Dividend Yield
- TREE N/A
- IGMS N/A
- EPS Growth
- TREE N/A
- IGMS N/A
- EPS
- TREE N/A
- IGMS N/A
- Revenue
- TREE $773,050,000.00
- IGMS $2,918,000.00
- Revenue This Year
- TREE $32.88
- IGMS $386.95
- Revenue Next Year
- TREE $16.82
- IGMS N/A
- P/E Ratio
- TREE N/A
- IGMS N/A
- Revenue Growth
- TREE 4.44
- IGMS 57.64
- 52 Week Low
- TREE $24.55
- IGMS $6.17
- 52 Week High
- TREE $62.49
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- TREE 41.39
- IGMS 31.94
- Support Level
- TREE $34.55
- IGMS $7.00
- Resistance Level
- TREE $44.51
- IGMS $10.80
- Average True Range (ATR)
- TREE 2.68
- IGMS 1.02
- MACD
- TREE 0.33
- IGMS -0.10
- Stochastic Oscillator
- TREE 55.65
- IGMS 10.39
About TREE LendingTree Inc.
LendingTree Inc is a United States-based company that is principally engaged in operating an online loan marketplace. The company provides online tools and resources that can help consumers find loans or other credit-based offerings They need, including mortgage loans, reverse mortgage, home equity, personal loans, auto loans, credit cards, student loans, small business loans, and other related offerings. The company offers consumers direct access to a broad range of lenders. They have three reportable segments which are Home, Consumer, and Insurance. The company generates match fees by matching consumers with lenders, and closing fees from lenders on loans when a transaction is closed. The company operates business solely in the United States.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.